Drug profile · INN
norfloxacin
APO-NORFLOXACIN
norfloxacin (APO-NORFLOXACIN) is a bacterial dna gyrase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — norfloxacin
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 1
- Programs
- 12
- Data quality
- 0.84
Quick answer
norfloxacin (APO-NORFLOXACIN) is a bacterial dna gyrase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA gyrase inhibitor
Primary target: Bacterial DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is norfloxacin?
norfloxacin (APO-NORFLOXACIN) is a bacterial dna gyrase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for norfloxacin?
APO-NORFLOXACIN is a marketed brand name for norfloxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of norfloxacin?
norfloxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.